Published in

BioMed Central, BMC Pregnancy and Childbirth, 1(10), 2010

DOI: 10.1186/1471-2393-10-8

Links

Tools

Export citation

Search in Google Scholar

Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study

Journal article published in 2010 by Joepe J. Kaandorp, Timo R. de Haan, Manon Jnl N. L. Benders, Maria G. van Pampus, Carin Ma A. Rademaker, Helen L. Torrance, Christine Willekes, Martijn A. Oudijk ORCID, Maurice Gaj A. J. Wouters, Kaandorp Jj, Ruurd M. van Elburg ORCID, Kitty Wm M. Bloemenkamp, Benders Mj, Claudia A. van Meir, Arie F. Bos and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Background Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy. Methods/Design The proposed trial is a randomized double blind placebo controlled multicenter study in pregnant women at term in whom the foetus is suspected of intra-uterine hypoxia. Allopurinol 500 mg IV or placebo will be administered antenatally to the pregnant woman when foetal hypoxia is suspected. Foetal distress is being diagnosed by the clinician as an abnormal or non-reassuring foetal heart rate trace, preferably accompanied by either significant ST-wave abnormalities (as detected by the STAN-monitor) or an abnormal foetal blood scalp sampling (pH